Building on these preclinical studies, Xu et al. conducted a first-in-human Phase 1 trial evaluating ESO-T01 product, a lentiviral vector designed to enable in vivo generation of BCMA-targeted CAR-T cells, in patients with R/R multiple myeloma [64]. This evidence concerns the gene TNFRSF17 and AL amyloidosis.